Evaluation of efficacy of mesalazine suppository in ulcerative colitis with rectal inflammation -Efficacy of on-demand therapy for induction and maintenance of remission -

Evaluation of efficacy of mesalazine suppository in ulcerative colitis with rectal inflammation -Efficacy of on-demand therapy for induction and maintenance of remission - - Evaluation of efficacy of mesalazine suppository in ulcerative colitis with rectal inflammation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011236

Enrollment

200

Registered

2013-07-20

Start date

2011-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Upon appearance of rectal bleeding, once daily administration of a 500 mg mesalazine suppository until disappearance of rectal bleeding.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Ulcerative colitis patients with rectal inflammation who has rectal bleeding or in remission. 2. Patients with the first attack or those in remission on salazopyrine or mesalazine less than 4 grams daily.

Exclusion criteria

Exclusion criteria: 1. Past history of adverse effect to mesalazine.

Design outcomes

Primary

Measure	Time frame
Time to disappearance of rectal bleeding Rate of disappearance of rectal bleeding Rate of adverse events	—

Countries

Japan

Contacts

Public ContactKatsuyoshi Matsuoka

Keio University School of Medicine Gastroenterlogy and Hepatology

matsuoka@z2.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026